James H. Stanker - 21 Jun 2021 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Chief Financial Officer
Signature: /s/ James H. Stanker by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 21 Jun 2021
Net transactions value: +$6,810
Form type: 4
Filing time: 22 Jun 2021, 17:09:57 UTC
Previous filing: 10 Jun 2021
Next filing: 09 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCSA	Common Stock	Purchase	$6,810	+1,000	+2.8%	$6.81	36,510	21 Jun 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.72 to $6.89, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Content

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.72 to $6.89, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.